Targeting TF-AKT/ERK-EGFR pathway suppresses the growth of hepatocellular carcinoma

Shan Zhou Huang, Meng Ning Wei, Jia Rong Huang, Zi Jian Zhang, Wen Ji Zhang, Qi Wei Jiang, Yang Yang, Huan Yu Wang, Hui Lin Jin, Kun Wang, Zi Hao Xing, Meng Ling Yuan, Yao Li, Xiao Shun He, Zhi Shi, Qi Zhou

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Tissue factor (TF) is a transmembrane glycoprotein to initiate blood coagulation and frequently overexpressed in a variety of tumors. Our previous study has showed that the expression of TF is upregulated and correlated with prognosis in hepatocellular carcinoma (HCC). However, the role and molecular mechanism of TF in the growth of HCC are still unclear. In vitro and in vivo functional experiments were performed to determine the effect of TF on the growth of HCC cells. A panel of biochemical assays was used to elucidate the underlying mechanisms. TF could promote the growth of HCC in vitro and in vivo by activating both ERK and AKT signaling pathways. TF induced EGFR upregualtion, and inhibition of EGFR suppressed TF-mediated HCC growth. In addition, TF protein expression was correlated with EGFR in HCC tissues. TF promotes HCC growth by upregulation of EGFR, and TF as well as EGFR may be potential therapeutic targets of HCC.

Original languageEnglish (US)
Article number150
JournalFrontiers in Oncology
Issue numberMAR
StatePublished - 2019


  • Epidermal growth factor receptor
  • Hepatocellular carcinoma
  • Tissue factor
  • Tumor growth

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Targeting TF-AKT/ERK-EGFR pathway suppresses the growth of hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this